BeiGene, Ltd.
06160
2021 12 31
2021 12 31 2020
2021 12 31 2020 12 31
867.4 280.8% 12 2020 12
31 325.1 105.3% 634.0
2020 12 31 542.3 542.3
2021 12 31 2020 12 31
648.5 33.0% 2,615.0
2021 12 31 2020 12 31
187.2 11.7% 1,413.4
2021 12 31 1.17
2020 12 31 1.47 20.4%
1
12 31
2021 2020
4,375,678 1,381,950
4 328 307
5 2,241,962 3,268,725
6 483,113 60,403
7 242,626 89,293
13 270,173 160,012
7,613,880 4,960,690
4 6,881 7,748
10 587,605 357,686
9 117,431 90,581
11 46,679 5,000
12 110,424 65,962
13 163,049 113,090
1,032,069 640,067
8,645,949 5,600,757
14 262,400 231,957
13 558,055 346,144
187,414 –
12 21,395 20,380
9 21,925 13,895
3 120,801 127,808
15 427,565 335,015
1,599,555 1,075,199
2
12 31
2021 2020
15 202,113 183,637
220,289 –
9 43,041 29,417
12 14,169 10,792
3 269,561 375,040
13 54,234 57,429
803,407 656,315
2,402,962 1,731,514
24
0.0001
9,500,000,000 2021 12 31
2020 12 31
1,334,804,281 1,190,821,941 133 118
11,191,007 7,414,932
20 17,950 6,942
(4,966,103) (3,552,749)
6,242,987 3,869,243
8,645,949 5,600,757
3
12 31
2021 2020
16 633,987 308,874
3 542,296 –
1,176,283 308,874
164,906 70,657
1,459,239 1,294,877
990,123 600,176
11 750 846
2,615,018 1,966,556
(1,438,735) (1,657,682)
(15,757) 1,998
5 15,904 37,490
(1,438,588) (1,618,194)
12 (25,234) (17,671)
(1,413,354) (1,600,523)
– (3,617)
(1,413,354) (1,596,906)
18 (1.17) (1.47)
18 1,206,210,049 1,085,131,783
(15.23) (19.13)
92,785,388 83,471,676
4
12 31
2021 2020
(1,413,354) (1,600,523)
20 13,714 23,603
23 1,865 (8,113)
20 (4,571) (419)
(1,402,346) (1,585,452)
– (3,489)
(1,402,346) (1,581,963)
5
12 31
2021 2020
(1,413,354) (1,600,523)
46,457 31,789
19 240,712 183,481
83,500 109,500
3 (112,486) (113,986)
5 (7,632) (11,826)
(41,085) (27,807)
23,510 (4,673)
(423,019) 10,363
(153,333) (58,906)
(107,128) (56,217)
20,008 95,835
140,044 185,012
407,703 –
(2,620) (25,503)
(1,298,723) (1,283,461)
(262,942) (117,508)
(2,147,881) (5,663,727)
3,146,891 2,751,075
(8,500) (109,500)
(43,409) –
(43,500) (26,681)
– (2,025)
640,659 (3,168,366)
6
12 31
2021 2020
20 3,392,616 –
20 50,000 4,232,017
3 – 616,834
8 – (28,723)
15 16,838 110,208
15 – (132,061)
15 406,449 323,697
15 (321,754) (12,247)
92,762 93,101
3,636,911 5,202,826
14,035 18,231
2,992,882 769,230
1,390,005 620,775
4,382,887 1,390,005
4,375,678 1,381,950
328 307
6,881 7,748
15,695 10,596
29,967 44,130
53,197 42,762
75,000 –
7
2019 12 31 801,340,698 79 2,925,970 (8,001) (1,955,843) 962,205 16,150 978,355
145,838,979 14 2,069,596 – – 2,069,610 – 2,069,610
206,635,013 21 2,162,386 – – 2,162,407 – 2,162,407
38,020,892 3 93,098 – – 93,101 – 93,101
(1,013,641) 1 – – – 1 – 1
– – 183,481 – – 183,481 – 183,481
– – – – – – (3,545) (3,545)
– – (19,599) – – (19,599) (9,116) (28,715)
– – – 14,943 – 14,943 128 15,071
– – – – (1,596,906) (1,596,906) (3,617) (1,600,523)
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,552,749) 3,869,243 – 3,869,243
115,055,260 12 3,392,604 – – 3,392,616 – 3,392,616
2,151,877 – 50,000 – – 50,000 – 50,000
28,778,893 3 92,759 – – 92,762 – 92,762
(2,003,690) – – – – – – –
– – 240,712 – – 240,712 – 240,712
– – – 11,008 – 11,008 11,008
– – – – (1,413,354) (1,413,354) – (1,413,354)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (4,966,103) 6,242,987 – 6,242,987
8
1.
Bruton BTK
PD-1
PARP1 PARP2
13
Novartis Pharma AG
2,200 30
90
30 3
14,500
(CMO)
2010 23
8,000
9
2021 12 31 42
BeiGene 101 – 100%
BeiGene AUS Pty Ltd. BeiGene Australia 56,947,230 100%
* 46,711,000 100%
* 5,050,000,000 100%
BeiGene (Canada) ULC 100 100%
BeiGene ESP, S.L. 3,000 100%
BeiGene France Sarl 7,500 100%
* 3,870,000,000 100%
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
BeiGene (Hong Kong) Co., Limited. 1 100%
* 4,000,000 100%
BeiGene International GmbH 20,000 100%
BeiGene (Italy) Sarl 10,000 100%
BeiGene Brasil Ltda. 50,000 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene Sweden AB 25,000 100%
BeiGene Turkey Medical Products Trade Limited Company 10,000 100%
BeiGene Ireland Limited BeiGene Ireland – 100%
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 100,000,000 100%
BeiGene Netherlands B.V. – 100%
BeiGene NZ Unlimited BeiGene NZ, Limited 100,000 100%
10
BeiGene Pharmaceuticals GmbH 20,000 100%
* 3,800,000 100%
* 7,000,000 100%
* 1,000,000 100%
* 534,344,310 100%
* 70,000,000 100%
BeiGene Singapore Pte., Ltd. 1 100%
* 144,000,000 100%
BeiGene Switzerland GmbH BeiGene Switzerland 20,000 100%
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 140 100%
BeiGene United Kingdom, Ltd. 100 100%
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC – 100%
BeiGene US Manufacturing Co., Inc 101,000,000 100%
BeiGene Hopewell Urban Renewal, LLC 75,000,000 100%
Pi Health, Ltd. 12,000,000 100%
Pi Health USA, LLC 5,000,000 100%
Newco 101 – 100%
*
11
2.
2020
MapKure,LLC MapKure
2020 6 MapKure
5 2020 11
8
2019 12 2019 12 740
740
2021 1 1
2021 11 2021 10 832
2021 12 15
12
3.
2021 12 31
2021 2020 12 31
12 31
2021 2020
484,646 –
53,671 –
3,979 –
542,296 –
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2) (3)
13
606
650,000,000
484,646,000 165,354,000
2021 12 31
2021 12 31
2021 12 31
53,421,000
2021 12
TIGIT
5
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000
1,150,000,000
50%
25%
14
606
(1)
(2)
(3) (4)
300,000,000
71,980,000
213,450,000
14,570,000
2021 12 31
3,979,000 250,000
2017 7 5
PD-1
PD-1 2017 8 31
PD-1 A&R PD-1
A&R PD-1 2019 6 14
15
A&R PD-1 263,000,000
92,050,000 2017 170,950,000 2017
12 13,000,000
Celgene Holdings East Corporation
A&R PD-1
A&R PD-1
606 (a)
(b)
250,000,000
2019 6
150,000,000
ABRAXANE
2020 3 25 (NMPA)
ABRAXANE
2021 10
180 ABRAXANE
ABRAXANE ABRAXANE
ABRAXANE
16
2019 10
2020 1 2
2019 2020 11
2020 7
2020 12
B
2021 7
(R/R)
1,250,000,000
K R A S G12C
LUMAKRAS (sotorasib)
LUMAKRAS
808
100%
2019 10 31
2020 1 2 174.85
15,895,001 20.5%
Anthony Hooper
2020 1
17
132.74 2,109,902,000
601,857,000
2,779,241,000 2,162,407,000
616,834,000
2020 12 31
2020
12 31
2,162,407
616,834
2,779,241
2021 2020 12 31
12 31
2021 2020
115,464 117,005
112,486 113,986
227,950 230,991
2021
12 31
791,059
18
2021 12 31 2020 12 31
12 31
2021 2020
120,801 127,808
269,561 375,040
390,362 502,848
2021 2020 12 31
12 31
2021 2020
1,893 (1,210)
(45,152) (9,750)
423 (660)
(42,836) (11,620)
2021 2020 12 31
110,303,000 38,392,000 2021 12 31 2020 12
31 106,790,000 122,828,000
2021 2020 12 31
12 31
2021 2020
83,500 109,500
15,000 15,800
43,394 –
141,894 125,300
19
Shoreline Biosciences, Inc.
2021 6 Shoreline Biosciences Inc. Shoreline
Shoreline iPSC
Shoreline
Shoreline
Shoreline
Shoreline 2022 1 45,000,000
2021
12 31
2021 12
LBL-007
LBL-007 LAG-3 2022
1 30,000,000 742,000,000
2021 12 31
EUSA Pharma
2020 1 EUSA Pharma EUSA
β
EUSA
EUSA 40,000,000
120,000,000
2020 12 31 2021
EUSA
20
Assembly Biosciences, Inc.
2020 7 Assembly Biosciences, Inc Assembly Assembly
Assembly ABI-H0731 ABI-H2158
ABI-H3733
Assembly
Assembly 40,000,000
503,750,000 Assembly
2020 12 31
2020 8
(BAT1706)
2020 9 10
2020 9 18
2020 10 20,000,000
145,000,000
2020 12 31 2021 11
Seagen, Inc.
2019 11 Seagen, Inc. Seattle Genetics, Inc.
Seagen
Seagen
Seagen
Seagen 20,000,000
Seagen
2019 12 31
21
Zymeworks,Inc.
2018 11 Zymeworks Zymeworks
HER2 ZW25(zanidatamab)
ZW49
Zymeworks Zymeworks Azymetic EFECT
Zymeworks zanidatamab ZW49 HER2
Zymeworks zanidatamab ZW49
ZW49 zanidatamab Zymeworks 40,000,000
Zymeworks zanidatamab ZW49
Azymetric EFECT Zymeworks 20,000,000
Zymeworks
2018 12 31
2021 2020 12 31
zanidatamab
2021 2020 12 31
22
4.
2021 12 31 2020 12 31 7,209,000
8,055,000
5.
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
2020 12 31
3,267,875 850 – 3,268,725
3,267,875 850 – 3,268,725
2021 12 31 2021
12 31
2021 12 31
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap
Leap 2021 9 Leap
7,250,000 Leap 2021 12 31
Leap 8.3%
13.1%
2021 2020 12 31
9,386,000 12,479,000
23
2021 12 31 2020 12 31
12 31
2021 2020
Leap 23,809 10,810
Leap 10,306 6,669
2021 12 31 2020 12 31
43,722,000 9,705,000 2021 2020
12 31
MapKure
2019 6 MapKure SpringWorks herapeutics,
Inc. SpringWorks BGB-3245 MapKure
B G B -3245 B-RAF V600B R A F
V600B-RAF RAF
MapKure10,000,000 A 71.4%
SpringWorks 3,500,000 A 25% 250,000
A 1.8%
MapKure
2020 6 MapKure SpringWorks
A
55.6% MapKure A
70%
2020 12 31 MapKure MapKure 55.6%
MapKure 11,307,000
10,000,000 MapKure 55.6%
2020 6 8
MapKure 2021 12 31 2020 12
31 1,176,000 491,000 2021 12 31
2020 12 31 MapKure 8,333,000 9,509,000
2020 7
11,782,000 80,000,000
60%
24
2021 12 31 19.3%
2021 2020 12 31
145,000 68,000 2021 12 31 2020 12 31
12,333,000 12,189,000
2021 2020 12 31
6.
12 31
2021 2020
483,528 60,515
(415) (112)
483,113 60,403
45 90
12 31
2021 2020
3 483,058 60,403
3 6 55 –
483,113 60,403
25
12 31
2021 2020
1 1 112 –
309 109
(6) 3
12 31 415 112
7.
12 31
2021 2020
78,140 19,330
9,397 1,378
155,089 68,585
242,626 89,293
8.
(CTA) (MAA)
2017 3
26
200,000,000
95%
100,000,000 5%
2017 3 7
900,000,000 2019 9
100%
95%
2020 9
5% 28,723,000 195,262,000
2020 11
9,116,000
100% 19,599,000
132,061,000 900,000,000 36,558,000 249,140,000
200,000,000
120,000,000
80,000,000
2020 10 80,000,000
118,320,000 2021 10 9
198,320,000 200,000,000
73,640,000
500,000,000 14,728,000
100,000,000 58,912,000 400,000,000
2021 12 31
15,693,000 100,000,000 15
9.
50 36 30
12
27
12 31
2021 2020
22,536 18,271
4,892 2,465
1,823 1,018
29,251 21,754
12 31
2021 2020
60,762 41,850
56,669 48,731
117,431 90,581
21,925 13,895
43,041 29,417
64,966 43,312
2022 12 31 24,225
2023 12 31 20,072
2024 12 31 16,103
2025 12 31 8,272
2026 12 31 1,546
70,218
(5,252)
64,966
12 31
2021 2020
19,962 17,571
37,454 17,634
12 31
2021 2020
3 3
5.15% 6.26%
28
10.
12 31
2021 2020
65,485 –
118,203 78,640
50,288 37,643
144,083 111,527
119,585 96,669
27,404 20,782
525,048 345,261
(124,286) (73,354)
186,843 85,779
587,605 357,686
2021 11 75,197,000 42
2021 12 31
2021 12 31 2020 12 31
12 31
2021 2020
90,229 48,824
63,361 29,858
17,178 4,507
16,075 2,590
186,843 85,779
2021 2020 12 31 44,742,000 30,943,000
29
11.
2021 12 31 2020 12 31
2021 12 31 2020 12 31
7,500 (3,250) 4,250 7,500 (2,500) 5,000
43,394 (965) 42,429 – – –
816 (816) – 816 (816) –
51,710 (5,031) 46,679 8,316 (3,316) 5,000
10
Merck KGaA 2018 12 31 EUSA Pharma
2018 9
2020 2
2024 2
13
12 31
2021 2020
965 –
750 846
1,715 846
30
2021 12 31
12 31
2022 3,314 750 4,064
2023 3,314 750 4,064
2024 3,314 750 4,064
2025 3,314 750 4,064
2026 3,314 750 4,064
2027 25,859 500 26,359
42,429 4,250 46,679
12.
12 31
2021 2020
(606,752) (369,066)
34,923 33,608
(866,759) (1,282,736)
(1,438,588) (1,618,194)
12 31
2021 2020
15,252 16,121
(9) (5,678)
805 68
16,048 10,511
7,516 (1,152)
(47,094) (27,030)
(1,704) –
(41,282) (28,182)
(25,234) (17,671)
31
12 31
2021 2020
(1,438,588) (1,618,194)
25% 25%
(359,647) (404,549)
185,874 218,473
(2,826) 8,436
(27,411) (22,032)
– (3,827)
210,306 209,085
(31,530) (23,257)
(25,234) (17,671)
1.8% 1.1%
12 31
2021 2020
84,766 33,512
625,114 358,425
14,982 13,981
82,060 58,835
937,069 724,779
11,571 9,066
1,755,562 1,198,598
(1,647,985) (1,134,585)
107,577 64,013
(11,322) (8,843)
(11,322) (8,843)
96,255 55,170
2021 12 31
2021 2020 12 31
210,306,000 209,085,000
32
2021 2020 12 31 3,644,005,000
2,230,857,000 2021 12 31 2023
2031 942,541,000 2025 2028
2,325,359,000 351,645,000
88,632,000 2035 2041
2021 2020 12 31
12 31
2021 2020
1 1 7,123 4,633
2,802 2,497
– (7)
12 31 9,925 7,123
2021 12 31 12
2021 2020
12 31
2021 12 31 2013 2021
2011 2021 2018 2021
2015 2021
2011 2021
2022
2021 12 31 2,863,000
0.01
2021 2020 12 31
2021 12 31
1,844,000
33
13.
12 31
2021 2020
87,239 71,341
58,579 30,392
12,010 12,651
5,052 6,619
1,695 1,347
78,538 25,996
27,060 11,666
270,173 160,012
12 31
2021 2020
109 109
14,140 16,984
(1)
24,237 29,778
17,162 10,913
6,609 5,962
100,792 49,344
163,049 113,090
(1)
12 31
2021 2020
139,966 106,765
213,922 143,302
71,560 66,131
45,661 14,373
59,639 11,874
27,307 3,699
558,055 346,144
34
12 31
2021 2020
46,352 49,139
7,814 8,113
68 177
54,234 57,429
14.
2021 12 31 2020 12 31
12 31
2021 2020
3 257,977 230,638
3 6 3,210 312
6 1 1,110 147
1 103 860
262,400 231,957
35
15.
2021 12 31 2020 12 31
12 31
2021 2020
2018/04/04 580,000 9 2027/04/04 (1) 1,255 8,000 307 2,000
2020/01/22 (2) 9 2029/01/20 (2) 1,569 10,000 – –
2020/09/24 200,000 (3) 4.5% 200,000 1,274,535 198,320 1,294,010
2020/09/24 500,000 (4) 4.5% 15,693 100,000 15,326 100,000
(5) 209,048 1,332,197 121,062 789,918
427,565 2,724,732 335,015 2,185,928
2018/04/04 580,000 9 2027/04/04 (1) 89,444 570,000 88,584 578,000
2020/01/22 (2) 9 2029/01/20 (2) 53,353 340,000 53,641 350,000
2020/11/09 378,000 9 2029/11/08 (6) 59,316 378,000 41,412 270,206
202,113 1,288,000 183,637 1,198,206
1. 2021 12 31
4.9% 2021 12 31 312,000
2,000,000
2. 2020 1 22
1,100,000,000
2020 12 31
1,100,000,000
350,000,000 2021 12 31 4.4%
3. 120,000,000 80,000,000
2021 10 8
2021
10 8 2022 10 9
2021 10 8 198,320,000
200,000,000
36
4. 100,000,000 400,000,000
(i)2021 11 9 (ii)
2021 10 8
(i)2022 11 9 (ii)
Hillhouse Capital
Hillhouse Capital Hillhouse Capital
5. 2021 12 31 2020 12 31
1,940,000,000
2021 4 19 2022 12 15 2021 12 31
206,449,000 1,332,197,000 2021 12 31
123,122,000 789,918,000 2021 12 31
4.2%
6. 2021 12 31
4.3% 2021 12 31 16,838,000
107,794,000
2021 12 31
2022 12 31 427,565
2023 12 31 15,300
2024 12 31 31,832
2025 12 31 38,027
2026 12 31 42,726
74,228
629,678
2021
2020 12 31 29,263,000 18,309,000
1,054,000 338,000
16.
37
2021 2020 12 31
12 31
2021 2020
748,824 324,672
(114,837) (15,798)
633,987 308,874
2021 2020 12 31
12 31
2021 2020
255,119 163,358
217,987 41,702
70,065 47,372
19,591 29,975
ABRAXANE – 17,770
45,956 8,496
12,515 –
12,754 201
633,987 308,874
2021 2020 12 31
12 31
2021 2020
1 1 11,874 3,198
114,837 15,798
(67,072) (7,122)
12 31 59,639 11,874
2021 3 1
2022 1 1
2021 12 31
2021 12 31
57,450,000
38
17.
12 31
2021 2020
164,906 70,657
10 44,742 30,943
1,459,239 1,294,877
9 22,536 18,271
11 1,715 846
720,551 466,962
240,712 183,481
38,810 13,372
1,000,073 663,815
(67) (1,492)
5,991 (4,813)
(13,528) (20,352)
106 9
2021 2020 12 31 463,441,000 346,203,000
18.
12 31
2021 2020
(1,413,354) (1,600,523)
– (3,617)
(1,413,354) (1,596,906)
1,206,210,049 1,085,131,783
(1.17) (1.47)
2021 2020 12 31
2021
2020 12 31
39
19.
2016
2016 1 2016
2016 2016 2 65,029,595
2016 2011 2011
2016
2011 2021 12 31
2011 2016 5,166,510 2016
2017 1 1
(i) (5)% (ii)
2018 1 1 29,603,616
2016 2018 8
2016
2018 12
2016 38,553,159
2020 6 2016
57,200,000 2030 4 13 2016
2021 12 31 2016 50,886,939
2018
2018 6 2018 2018
12,000,000
5635(c)(4)
5635(c)(4) 2018
2018
2016 2018 8
2018
2021 12 31 2018 9,344,659
40
2018
2018 6 2018
3,500,000 2018 8
2018 12
3,855,315 7,355,315
6
15%
10%
1 2
ADS ADS
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
2020 8 31 485,069 164.06 12.62 139.45 10.73 5,203
2020 2 28 425,425 145.54 11.20 123.71 9.52 4,048
2019 8 30 233,194 143.75 11.06 122.19 9.40 2,192
2019 2 28 154,505 137.05 10.54 116.49 8.96 1,385
1
2
2021 12 31 5,194,546
10
41
2011 2016 2018
2019 12 31 108,417,254 3.96
8,999,536 13.54 7.15
(29,707,587) 2.82 416,509
(2,717,488) 7.22
2020 12 31 84,991,715 5.27
6,244,524 26.46 12.40
(17,233,853) 4.52 367,110
(1,797,498) 13.27
2021 12 31 72,204,888 7.08 5.81 1,026,958
2021 12 31 55,576,828 4.31 5.08 919,118
2021 12 31 70,043,242 6.79 5.73 1,012,938
2021 12 31 14,466,414
88,394,000 2.1
2021 2020 12 31
53,571,000 55,127,000
42
12 31
2021 2020
9.94 ~ 14.97 4.95 ~ 11.89
1.1% ~ 1.7% 0.6% ~ 1.1%
2.8 2.8
51% ~ 59% 58% ~ 59%
0% 0%
10 10
2016
2019 12 31 75,000 2.27
– –
(75,000) 2.27
– –
2020 12 31 – –
– –
– –
– –
2021 12 31 – –
2021 12 31 – –
2021 2020 12 31
2021 12 31
43
2016 2018
2019 12 31 26,852,267 10.72
18,820,581 14.20
(7,302,828) 10.88
(3,493,048) 11.36
2020 12 31 34,876,972 12.50
17,173,767 25.58
(10,703,381) 12.23
(5,264,376) 15.82
2021 12 31 36,082,982 18.33
2021 12 31 31,392,194 18.33
2 0 2 1 12 31
469,862,000 2.6
2021 2020 12 31
12 31
2021 2020
114,357 92,999
126,355 90,482
240,712 183,481
44
20.
2019 12 31 (9,291) 1,290 – (8,001)
23,475 1,073 (8,113) 16,435
(1)
– (1,492) – (1,492)
23,475 (419) (8,113) 14,943
2020 12 31 14,184 871 (8,113) 6,942
13,714 (4,504) 309 9,519
(1)
– (67) 1,556 1,489
13,714 (4,571) 1,865 11,008
2021 12 31 27,898 (3,700) (6,248) 17,950
(1)
45
21.
2021 2020 12 31
2020 1
(ADS) 174.85 15,895,001
20.5% 2,779,241,000
2020 3 17 (BeiGene, Ltd.)
2020 9 24
20.6%
20.4% (i)
(ii)
2020 12 1 (a)
20% (b)
60 (c)2023 12 1
2020 7 S-3 333-238181
(Hillhouse Capital) Baker Bros. Advisors LP
145,838,979 0.0001
14.2308 185.00
2,069,610,000 421,443,000
29,614,832
2019 10 31 2019 12 6 2020 9 24
(SPA) 2021 9
165,529 ( 2,151,877
50,000,000
2021 12
192.60
391.68 115,055,260
3,392,616,000
22.
46
10%
50%
2021 2020 12 31
10%
2021 2020 12 31
799,574,000 119,776,000
23.
2021 2020 12 31
63,772,000 23,717,000
401(k) 401(k) 401(k)
401(k) 2021 4%
2021 2020 12 31 401(k) 7,483,000
4,840,000
2021 2020 12 31
2,986,000 2,960,000
2021 2020
12 31 34,517,000 23,566,000
26,703,000 15,453,000
2020 12 31
20
47
2022 1,604,000
2021
12 31
2022 44
2023 68
2024 528
2025 271
2026 197
2027 – 2031 3,760
4,868
24.
2021 12 31 168,687,000 75,976,000
92,711,000
2021 12 31 42,394,000
1,250,000,000
2021 12 31 791,059,000
2021 12 31 27,985,000
15,000,000 2021 12 31
12,750,000
48
(CRO)
25.
12 31
2021 2020
517,173 290,646
495,265 18,228
163,845 –
1,176,283 308,874
2021 12 31
2021 12 31 379,607,000
115,658,000 2020 12 31
2021 12 31
49
26.
2021 12 31
(i) (iii)
(1,459,239) (21,541) – (1,480,780)
(990,123) (27,189) – (1,017,312)
(1,438,588) (48,730) – (1,487,318)
25,234 5,253 (56,237) (25,750)
(1,413,354) (43,477) (56,237) (1,513,068)
(1,413,354) (43,477) (56,237) (1,513,068)
2020 12 31
(i) (iii)
(1,294,877) (5,338) – (1,300,215)
(600,176) (12,280) – (612,456)
(1,618,194) (17,618) – (1,635,812)
17,671 1,143 (41,404) (22,590)
(1,600,523) (16,475) (41,404) (1,658,402)
(1,596,906) (16,475) (41,404) (1,654,785)
50
2021 12 31
(i) (ii) (iii)
110,424 5,253 – – 125,744
10,067* – –
8,645,949 15,320 – – 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(4,966,103) (48,730) – (56,237) (5,568,781)
5,253 – –
(115,252)* (307,894)* (79,818)*
6,242,987 15,320 – – 6,258,307
2020 12 31
(i) (ii) (iii)
65,962 1,143 – – 76,029
8,924* – –
5,600,757 10,067 – – 5,610,824
7,414,932 17,618 – 41,404 7,927,963
107,701* 307,894* 38,414*
(3,552,749) (17,618) – (41,404) (4,055,713)
1,143 – –
(98,777)* (307,894)* (38,414)*
3,869,243 10,067 – – 3,879,310
*
51
(i)
2021 12 31
48,730,000
2020 17,618,000 2021 12 31
5,253,000 2020 1,143,000
125,319,000 10,067,000
2020 12 31 115,252,000 2020 12 31
2021 1 1
(ii)
2016 2
307,894,000
307,894,000
52
(iii)
2016-09
2021 12 31 2020 12 31
2021 12 31 56,237,000 2020
41,404,000
2020 12 31 79,818,000
79,818,000 2021 1 1
(iv)
2019 1 1
16
2021 12 31 2021 12 31
(v)
2021 12 31 2021 12 31
27.
2021 12 31 2020 12
31
53
3
BTK)
PD-1
PARP1 PARP2
(EU)
13
2,200
30 90
30
3
14,500
(CMO)
2010
23 8,000
54
2022 3 11 NMPA PD-1
(MSI-H)
(dMMR)
2022 2 22 FDA
(CLL) (SLL)
sNDA CLL
(PDUFA) FDA 2022 10 22
2022 2 22 (EMA) BTK
(CLL) (MZL)
2022 2 17
(WM)
WM
2022 1 28 NMPA (CDE)
(CLL) (SLL)
sNDA
(BTD)
2022 1 20 NMPA (CDE)
sNDA
WM
2022 1 6 NMPA PD-1
(NSCLC)
55
2021 12 20
TIGIT
(ociperlimab) ociperlimab
2023
ociperlimab
ociperlimab
ociperlimab
5
2021 12 20 BIC
BIC
2021 12 15 (UK) (MHRA)
WM
WM
2021 12 13
LBL-007
LBL-007 LAG-3
2021 12 2 PD-1
PARP
2022 1 1
56
2021 12 2 NMPA EUSA
(HIV) 8 (HHV-8)
Castleman (MCD) MCD(iMCD)
2021 11 23
115,055,260 0.0001
2021 10 31
8.62%
2021 11 30
192.60
1.00 0.81996 1.00 6.3924
234.89 (ADS)391.68 2021 12
14 2021 12 15
688235
222 35
2021 11 23
(WM) WM
27
2021 11 23
42
2021 11 14 NewBridge Pharmaceuticals
(MCL)
57
1. 700
ociperlimab
TIGIT
BGB-11417
BCL2 2022
2022 2023
OX40 TIM3 PI3K delta HPK-1 50
2.
2,200
(CRO)
58
3.
3,100
4.
WM
45
5.
59
2021 1
(1)
(2)
60
2021 12
TIGIT
5
(1)
(2)
(3)
61
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
62
sitravatinib Mirati Therapeutics, Inc. Mirati
ZW25(zanidatamab) ZW49 Zymeworks Inc. Zymeworks
HER2
(BAT1706)
63
ADS
64
2021 12
65
2021 2020 12 31
2021 2020 12 31
12 31
2021 2020 %
633,987 308,874 325,113 105.3%
542,296 – 542,296
1,176,283 308,874 867,409 280.8%
164,906 70,657 94,249 133.4%
1,459,239 1,294,877 164,362 12.7%
990,123 600,176 389,947 65.0%
750 846 (96) (11.3)%
2,615,018 1,966,556 648,462 33.0%
(1,438,735) (1,657,682) 218,947 (13.2)%
(15,757) 1,998 (17,755) (888.6)%
15,904 37,490 (21,586) (57.6)%
(1,438,588) (1,618,194) 179,606 (11.1)%
(25,234) (17,671) (7,563) 42.8%
(1,413,354) (1,600,523) 187,169 (11.7)%
– (3,617) 3,617 (100.0)%
(1,413,354) (1,596,906) 183,552 (11.5)%
66
2020 12 31 3.089 2021 12 31
8.674 12
2021 2020 12 31
12 31
2021 2020 %
633,987 308,874 325,113 105.3%
484,646 – 484,646
53,671 – 53,671
3,979 – 3,979
542,296 – 542,296
1,176,283 308,874 867,409 280.8%
12 31
2021 2020 %
255,119 163,358 91,761 56.2%
217,987 41,702 176,285 422.7%
70,065 47,372 22,693 47.9%
19,591 29,975 (10,384) (34.6)%
ABRAXANE – 17,770 (17,770) (100.0)%
45,956 8,496 37,460 440.9%
12,515 – 12,515
12,754 201 12,553 6,245.3%
633,987 308,874 325,113 105.3%
67
2021 12 31 6.34 3.089
2020 7
2021 8
2021 3 1
2022 1 1
2021 12 31
5,750 2021 12 31
2021 12 31
2.18
422.7% 2021 12 31
1.157
1,820 MCL FDA WM
MZL 2021 12 31
1.012 331%
CLL SLL
2021 12 31
2.551
56.2% 2021 12 31
2021 3 2022 1
2021 4,560
2021 12 31 5.423
4.846 2021 12 31
5,370
400 3 2020
12 31
2020 12 31 7,070 2021 12 31
1.649
68
2021 12 31 4.691
2020 12 31 2.382
77.1% 2021 12 31
74.0% 2021
2021 12 31
2020 12 31
2020 12 31 12.949 1.644
12.7%) 2021 12 31 15 2021
2020 12 31
12 31
2021 2020 %
477,761 502,399 (24,638) (4.9)%
83,500 109,500 (26,000) (23.7)%
1
115,464 117,005 (1,541) (1.3)%
676,725 728,904 (52,179) (7.2)%
782,514 565,973 216,541 38.3%
1,459,239 1,294,877 164,362 12.7%
1. 2021 12 31 2.28
1.155 1.125
2021 12 31
CRO
69
2.165
1.09
5,240
2,140
1,770
1,610
2020 12 31 6.002 3.899
65.0% 2021 12 31 9.901
1.757
1.191
5,930
3,590
70
2020 12 31 200
1,780 888.6% 2021 12 31 1,580
2020 31
12 3,750 2,160
2021 12 31 1,590 2021 12 31
Leap Therapeutics
2020 12 31
MapKure LLC
2021 12 31 2,520 2020 12 31
1,770 2021 12 31
2021 12 31
(1) 28 (2) 244
38 (3) 23.3
2020 12 31 60.4 699.8% 2021 12
31 483.1 2021 12 31 Ociperlimab
300
2020 12 31 89.3 171.7% 2021 12 31
242.6
71
2021 2020 12 31
12 31
2021 2020
87,239 71,341
58,579 30,392
12,010 12,651
5,052 6,619
1,695 1,347
78,538 25,996
27,060 11,666
270,173 160,012
2020 12 31 160.0 68.8%
2021 12 31 270.2 (i) (ii)
2020 12 31 357.7 64.3%
2021 12 31 587.6
2021 11 42
72
2021 2020 12 31 262.4
232.0
12 31
2021 2020
3 257,977 230,638
3 6 3,210 312
6 1 1,110 147
1 103 860
262,400 231,957
2021 2020 12 31
12 31
2021 2020
139,966 106,765
213,922 143,302
71,560 66,131
45,661 14,373
59,639 11,874
27,307 3,699
558,055 346,144
2020 12 31 346.1 61.2%
2021 12 31 558.1 (i)
(ii)
(iii) 2021
73
2021 12 31
12 31
2021 2020
4,382,887 1,390,005
2,241,962 3,268,725
629,678 518,652
2021 2020 12 31 14
16 2021 12 31 50
2017 9
2021 12 31
12
2021 6 28 2021 1
2021 12 15
192.60
391.68 115,055,260
34
2021 1
6.5
2021 12
TIGIT
2022 1 3 2021
12 31
74
2021 2020 12 31
12 31
2021 2020
1,390,005 620,775
(1,298,723) (1,283,461)
640,659 (3,168,366)
3,636,911 5,202,826
14,035 18,231
2,992,882 769,230
4,382,887 1,390,005
2021 12 31 13
14 1.183 2.33
2020 12 31 13
16 1.665
1.506
75
2021 12 31 6.407
21 2.629 4,340
4,350 850 31
2020 12 31 32
57 1.175 1.095
28
2021 12 31 36 2021
12 34 4.064
9,280
5,000 1,680
3.218
2020 12 31 52
28
21
9,310 4.339
1.443
5% 2,870
2021 12 15
217
76
SEC
2020 5 SEC
77
2021 12 31
70,218 24,225 45,993
168,687 110,345 58,342
629,678 427,565 202,113
57,299 24,336 32,963
791,059 244,800 546,259
12,750 4,250 8,500
27,985 5,659 22,326
7,814 1,604 6,210
42,394 42,394 –
1,807,884 885,178 922,706
2021 12 31 1.687
7,600 BMS
9,270 BMS
4.276 2.021
15
78
12.5
2021 12 31
8
1,500 2021
12 31 1,280
2021 12 31 2,800
2021 12 31
160
2021 12 31 4,240
42 7,520
79
2021 12 31 57
2021 12 31 2020 12 31 44
14 720 810
22 33
2021 12 31
100 2021 12 31
1,510 670
2021 12 31 2020 12 31 483,113,000
60,403,000
80
1994
2005
2021
2020 12 31 2.3% 6.3%
2021 12 31
81
2021 12 31
2020 12 31 13.4% 10.1%
2021 12 15
2021 12 31
2021 12 31
75.2 42
2021 12 31
2021 12 31
2021 12 31 8,000
2020 12 31 5,100
2021 12 31 10 2020 663.8
2021 12 31 7.2
2020 12 31 8.1
145.8 2020 12 31 148.6
82
2021 12 31 2020 12 31
2021 12 31
2
83
A.2.1 2022 1 1
C.2.1
Ranjeev Krishana
84
3.21
C.3.3 C.3.7
Thomas Malley Corazon (Corsee)
D. Sanders Anthony C. Hooper Thomas
Malley 3.10(2) 3.21
3.25
B.1.2
Ranjeev Krishana
A.5.2
Donald W. Glazer Michael Goller Alessandro Riva
Anthony C. Hooper Donald W. Glazer
85
B.8
Scott A. Samuels
Scott A. Samuels
21
2021 12 15
115,055,260
86
13.51(B)(1)
13.51(B)(1)
Corazon (Corsee) D. 2021 2 24
Sanders
2021 2 24
Anthony C. Hooper 2021 2 24
2022 1 31
2020 2 26 2021 2 24
2020 1 2
174.85 15,895,001
206,635,013
20.5% 2,779,241,000 (a) 2019 10
30 30
36% (b) 1.00 7.84 2019
10 31 26% (c)
2019 10 31 26%
87
2019 11 29
2021 12 31
2021
12 31
2020 2021
12 31 12 31
(%)
(a)
2,779,241 100% 1,095,499 1,869,643 909,598
(a)
12.5
2019 11 29
2025 2019 11 1
2019 12 9 2020 1 3
2020 9 24
20.6%
20.4% 75,000,000
90
2020 12 1
(a) 20%
(b) 60 (c)
88
2020 3 18 2020 9 25
2020 10 9
2021 9
165,529 2,151,877
50,000,000
7
2020 7 15 2020
202,995,338
2020 7 12 14.2308
185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2021 12 31 10.9 9.8
89
2021 12 15
2021 6 16 2021
192.60
234.89 391.68
115,055,260
3,392,616,000
(i) (ii) (iii)
(iv) (v)
2020 11 16 2021 1 29 2021
4 20 2021 5 14 2021 6 1 2021 6 21 2021 6 28
2021 6 30 2021 7 9 2021 7 28 2021 10 15 2021
11 16 2021 11 23 2021 11 24 2021 11 29 2021
11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13
2021 12 21 2021 12 28 2021 4 30
2021 12 31 34
Thomas
Malley Anthony C. Hooper Corazon (Corsee) D. Sanders Thomas
Malley Corazon (Corsee) D. Sanders Anthony C.
Hooper Thomas Malley
2021 12 31
90
2021 12 31
2021 12 31
4400
730 730
2022 1 31 2022 2 1
11 12 2022 2 1 Margaret Han Dugan
Alessandro Riva
2022 2 1 Dugan
Riva
2022 2 25 Dugan
2021 12 31
2022 6 22
2022 4 18
2022
4 18
183 17
1712-1716
91
(www.hkexnews.hk) (www.
beigene.com) 2021 12 31
2022 3 30
Anthony C. Hooper Margaret
Han Dugan Donald W. Glazer Michael Goller Ranjeev Krishana
Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders
92